JP Morgan Chase’s Editas Medicine EDIT Stock Holding History

JP Morgan Chase’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,200	Closed	-$974K	–	6402
2021 Q1	$974K	Hold	23,200	–	–	﹤0.01%	4255
2020 Q4	$1.63M	Buy	+23,200	New	+$953K	﹤0.01%	3630
2019 Q1	–	Sell	-110,000	Closed	-$2.5M	–	5827
2018 Q4	$2.5M	Buy	+110,000	New	+$2.99M	﹤0.01%	3121
2018 Q3	–	Sell	-45,000	Closed	-$1.61M	–	5699
2018 Q2	$1.61M	Sell	45,000 -35,000	-44%	-$1.24M	﹤0.01%	3549
2018 Q1	$2.65M	Buy	80,000 +40,000	+100%	+$1.43M	﹤0.01%	3068
2017 Q4	$1.23M	Buy	+40,000	New	+$1.01M	﹤0.01%	3602

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's EDIT Position: Q1 2026 in Review

JP Morgan Chase increased its Editas Medicine (EDIT) stake by 149% in Q1 2026, buying an estimated $2.46M and bringing the position to 1,947,384 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3451.

JP Morgan Chase first reported a position in EDIT in Q1 2016 and has held it in 39 quarters since. The position peaked at $62.4M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

JP Morgan Chase held 1,947,384 shares of Editas Medicine worth $4.34M as of Q1 2026.
JP Morgan Chase bought 1,164,280 Editas Medicine shares in Q1 2026, an estimated $2.46M.
Editas Medicine made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3451 holding.
JP Morgan Chase first reported a position in Editas Medicine in Q1 2016 and has held it in 39 quarters since.
JP Morgan Chase's Editas Medicine position peaked at $62.4M in Q2 2021.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.